BLA 761310 · Immunogen INC
Elahere
Mirvetuximab Soravtansine-Gynx · Injection
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Nov 14, 2022: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
Last checked: Nov 20, 2026Latest source record: Jul 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Nov 14, 2022
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
31
7 Phase 3, 9 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Mirvetuximab Soravtansine" as an intervention, any sponsor and status, largest first.
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07213804 · 1,630 participants (planned) · Start Oct 22, 2025 · Primary completion Nov 2028
Drug: Sofetabart Mipitecan; Paclitaxel and 6 more · For: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Burbank, California · 264 sites in all
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07218809 · 1,100 participants (planned) · Start Dec 29, 2025 · Primary completion Nov 17, 2028
Drug: AZD5335; Mirvetuximab Soravtansine (MIRV) and 3 more · For: Epithelial Ovarian Cancer
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 299 sites in all
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05445778 · 520 participants · Start Mar 15, 2023 · Primary completion Apr 2027
Drug: Mirvetuximab soravtansine plus Bevacizumab; Bevacizumab · For: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Irvine, California · 264 sites in all
AbbVieAbbVie (ABBV)
NCT04209855 · 453 participants · Start Dec 31, 2019 · Primary completion Mar 6, 2023
Drug: Mirvetuximab Soravtansine; Paclitaxel and 2 more · For: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 214 sites in all
- A Study of PHST001 in Advanced Solid TumorsPivotal-lookingRecruiting
Pheast TherapeuticsIndustry
NCT06840886 · 426 participants (planned) · Start Mar 31, 2025 · Primary completion Apr 2029
Drug: PHST001; Paclitaxel and 7 more · For: Advanced Solid Tumors; Ovarian Cancer; Endometrial Cancer and 6 more
Sites: Beverly Hills, California; Los Angeles, California; Palo Alto, California · 20 sites in all
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07059845 · 400 participants (planned) · Start Nov 13, 2025 · Primary completion Jan 2029
Drug: Mirvetuximab Soravtansine; Bevacizumab and 1 more · For: Ovarian Cancer
Sites: La Jolla, California; Solvang, California; Gainesville, Florida · 86 sites in all
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerPivotal-lookingCompleted
ImmunoGen, Inc.Industry
NCT02631876 · 366 participants · Start Mar 2, 2016 · Primary completion Jan 2019
Drug: Mirvetuximab soravtansine; Paclitaxel and 2 more · For: Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer and 1 more
Sites: Birmingham, Alabama; Tempe, Arizona; Tucson, Arizona · 131 sites in all
ImmunoGen, Inc.Industry
NCT02606305 · 264 participants · Start Mar 2, 2016 · Primary completion Mar 12, 2021
Drug: Mirvetuximab soravtansine; Bevacizumab and 3 more · For: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Sites: Los Angeles, California; Boston, Massachusetts; Reno, Nevada · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Elahere (Mirvetuximab Soravtansine-Gynx) · HCPCS J9063
2024 spending
$213M
Beneficiaries
1,757
9,214 claims
Per beneficiary
$121,204
2024 ASP limit $66.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $88,328,906 |
| 2024 | $212,956,170 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis.
Rehim S, Yuan S, Wang H · PLoS One 2024 · Systematic Review, Meta-Analysis
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore KN, Oza AM, Colombo N, et al. · Ann Oncol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Richardson DL, Moore KN, Vergote I, et al. · Gynecol Oncol 2024 · Clinical Trial, Phase I, Multicenter Study
- The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis.
Kim ET, Kim JH, Park EY, et al. · Cancer Med 2024 · Systematic Review, Meta-Analysis
Sponsor: Immunogen INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.